Abzena PLC Exercise of options (5025U)
October 24 2017 - 11:15AM
UK Regulatory
TIDMABZA
RNS Number : 5025U
Abzena PLC
24 October 2017
Abzena plc
Exercise of options
Cambridge, UK, 24 October 2017 - Abzena plc (AIM: ABZA,
'Abzena', the 'Company' or the 'Group') announces that on 23
October 2017 177,894 new ordinary shares of GBP0.002 each in the
Company ('Ordinary Shares') were issued and allotted following the
exercise of share options by employees and former employees. The
new Ordinary Shares rank pari passu with the Company's existing
issued Ordinary Shares and have been admitted to trading on AIM
under the Company's block admission.
Total voting rights
Following the issue of 177,894 new Ordinary Shares pursuant to
the option exercise set out above, the Company's issued share
capital comprises 213,817,130 Ordinary Shares with voting rights.
No Ordinary Shares are held in treasury. The total number of voting
rights in the Company is therefore 213,817,130. This figure of
213,817,130 Ordinary Shares may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black / +44 20 7260
Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Alex Shaw 2020
abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'Abzena inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'Abzena inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel
payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEASELAFFXFFF
(END) Dow Jones Newswires
October 24, 2017 11:15 ET (15:15 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2023 to Apr 2024